A. C. Dueck

机构：Mayo Clinic, Mayo Clinic in Arizona

发表论文 39 篇 · 总被引 190 次 · h-index 7

代表论文

• Phase II trial combining nab-paclitaxel (NP), gemcitabine (G), and bevacizumab (B) in patients (pts) with metastatic breast cancer (MBC): NCCTG N0735. (2011 · Journal of Clinical Oncology · 被引 13)
• Effect of PTEN protein expression on benefit to adjuvant trastuzumab in early-stage HER2+ breast cancer in NCCTG adjuvant trial N9831. (2011 · Journal of Clinical Oncology · 被引 9)
• Are we assuming too much with our statistical assumptions? Lessons learned from the ALTTO trial (2019 · Annals of Oncology · 被引 8)
• Effect of IGF1R protein expression on benefit to adjuvant trastuzumab in early-stage HER2+ breast cancer in NCCTG N9831 trial. (2011 · Journal of Clinical Oncology · 被引 7)
• International Consensus-Driven Recommendations for Patient-Reported Outcome Research Objectives in Early Phase Dose-Finding Oncology Trials: OPTIMISE-ROR (2026 · Journal of Clinical Oncology · 被引 6)
• Abstract PD5-07: The impact of early lapatinib-induced rash on disease-free and overall survival in patients treated within the ALTTO phase III randomized trial (2016 · Cancer Research · 被引 6)